Last year, hedge-fund manager Martin Shkreli made headlines for all the wrong reasons when he bought anti-parasitic drug Daraprim and jacked up the price overnight from $US13.50 to $750 a tablet.
To prove how much of a dick move that was, a group of high school students in Australia has now created 3.7 grams of Daraprim's active ingredient in their chemistry lab for just $20 - an amount that would sell in the US for between $35,000 and $110,000 at the current rate charged by Shkreli's company.
For perspective, a tablet's worth of the students' medicine costs just $2 to make, as opposed to the $750 Shkreli's company Turing Pharmaceuticals sells it for in the US (the company cut the drug's price by 50 percent for US hospitals following the backlash, but didn't change the cost for private patients).
Daraprim is on the World Health Organisation's list of essential medicines. It's an anti-parasitic medicine that's used to treat infections such as toxoplasmosis and malaria, particularly in those with low immunity, such as people with HIV, chemotherapy patients, and pregnant women.
Get the other nerdy details about the drug here